Product Description
Bapineuzumab is a humanized form of murine monoclonal antibody 3D6, which targets the N-terminal region of Abeta. (Sourced from: https://www.alzforum.org/therapeutics/bapineuzumab)
Mechanisms of Action: AB Degrader
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: Johnson & Johnson
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-002133-20 | P3 |
Completed |
Alzheimer Disease |
2015-07-13 |
|
| SUMMIT AD | P2 |
Completed |
Alzheimer Disease |
2013-01-01 |
|
| 3133K1-3002 | P3 |
Terminated |
Alzheimer Disease |
2012-11-01 |
|
| 2009-015079-29 | P3 |
Completed |
Alzheimer Disease |
2012-10-25 |